Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Clinical Trials in China

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University481 Fudan University478 Second Affiliated Hospital, Zhejiang University, School of Medicine401 Ruijin Hospital289 Peking Union Medical College Hospital279
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials in this register

19187 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
169
Chongqing, Luoyang, Zhengzhou, Wuhan, Changsha, Hohhot, Nanchang, Changchun
2023-06-26
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
38
Shanghai
2023-06-25
Active, closed
Kun Sun
Not applicable
12
Chengdu, Shanghai
2023-06-25
Recruiting
Sirolimus in the Treatment of Refractory/Relapsed wAIHA
NCT05925023Warm Autoimmune Hemolytic Anemia
DrugSirolimus
Peking Union Medical College Hospital
Not applicable
22
Beijing
2023-06-24
Active, closed
West China Second University Hospital
Not applicable
5,000
Chengdu
2023-06-24
Recruiting
Postoperative Effects of Different Enterostomy Approaches
NCT05853094Colorectal Cancer, Colorectal Neoplasms Malignant, Intestinal Neoplasms, Malignant
Fudan University
Not applicable
300
Shanghai
2023-06-23
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Nanjing
2023-06-22
Recruiting
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
NCT05427370Coronary Artery Disease, Heart Failure Systolic
Sunnybrook Health Sciences Centre
Not applicable
754
Jilin City, Shanghai
2023-06-22
Recruiting
A Study of FZ-AD004 in Patients With Advanced Solid Tumors
NCT05914545Advanced and Metastatic Solid Tumor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1
121
Hangzhou, Shanghai, Xuzhou
2023-06-21
Recruiting
Shanghai East Hospital
Early Phase 1
30
Shanghai
2023-06-21
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
59
Guangzhou
2023-06-21
Recruiting
Omission of SLNB in CN0 Early Breast Cancer
NCT05935150Breast Cancer, Clinically Assessed Negative Axillary Lymph Nodes, Sentinel Lymph Node
The First Affiliated Hospital with Nanjing Medical University
Not applicable
311
Nanjing
2023-06-21
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2
60
Wuhan
2023-06-21
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 4
368
Shanghai
2023-06-20
Active, closed
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3
167
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Wuhan, Shenyang, Shanghai, Chengdu
2023-06-20
Recruiting
Study of MHB088C for Patients With Advanced Solid Malignant Tumors
NCT07102004Advanced/Metastatic Solid Tumors
DrugQLC5508
Qilu Pharmaceutical Co., Ltd.
Phase 1/2
515
Beijing
2023-06-20
Recruiting
A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities
NCT07394374Solid Tumors Harboring NTRK Fusion, NTRK, NTRK Gene Fusion, NTRK Fusion Positive
Cullgen (Shanghai),Inc
Phase 1/2
42
Beijing, Chengdu, Guangzhou, Hangzhou, Taiyuan
2023-06-20
Recruiting
Huazhong University of Science and Technology
Phase 2
40
Wuhan
2023-06-20
Recruiting
Hoffmann-La Roche
Phase 1/2
320
Changsha, Harbin, Shanghai
2023-06-20
Recruiting
Fudan University
Phase 3
764
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-20
Recruiting
Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC
NCT05956639Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
DrugRezvilutamide
The First Affiliated Hospital with Nanjing Medical University
Phase 3
100
Nanjing
2023-06-20
Recruiting
Geneplus-Beijing Co. Ltd.
Observational
100
Shanghai
2023-06-19
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4
360
Hefei, Beijing, Lanzhou, Nanning, Shijiazhuang, Tianjin, Zhengzhou, Wuhan
2023-06-19
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
480
Shanghai
2023-06-19
Recruiting
Wenwen Wang
Observational
20,000
Wuhan
2023-06-19
Recruiting
Sun Yat-Sen University Cancer Center
Phase 2
120
Guangzhou
2023-06-19
Recruiting
Zhujiang Hospital
Observational
500
Guangzhou
2023-06-18
Recruiting
Takeda
Phase 3
408
Hefei, Wuhu, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Huizhou
2023-06-16
Recruiting
FengYan Jin
Observational
50
Changchun
2023-06-15
Recruiting
Oral Metronomic Vinorelbine and PD-1 Inhibitors in Elderly Non-small Cell Lung Cancer
NCT07041320Lung Cancer (NSCLC), Elderly (People Aged 65 or More)
Anhui Chest Hospital
Observational
40
Hefei
2023-06-15
Recruiting
Circulating Tumor DNA Methylation Guided Postoperative Follow-up Strategy for Non-metastatic Colorectal Cancer
NCT05904665Non-metastatic Colorectal Cancer, Circulating Tumor DNA Methylation
Fudan University
Not applicable
584
Shanghai
2023-06-15
Recruiting
Strategies for Toddler ASD With Remote-therapy (STAR) Model for ASD
NCT05901558Autism Spectrum Disorder, Therapy
Children's Hospital of Fudan University
Not applicable
110
Shanghai
2023-06-15
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
58
Beijing, Fuzhou, Weifang, Shanghai, Taiyuan, Tianjin
2023-06-14
Recruiting
Hunan Cancer Hospital
Phase 2
41
Changsha
2023-06-14
Recruiting
GlaxoSmithKline
Phase 1/2
123
Suzhou
2023-06-14
Recruiting
Helical Tomotherapy in Multiple Myeloma
NCT05970198Multiple Myeloma
Fuling Zhou
Not applicable
58
Wuhan
2023-06-14
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 1/2
156
Shanghai
2023-06-13
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
300
Guangzhou
2023-06-13
Recruiting
Photoacoustic/Ultrasound Imaging for Breast Nodule Diagnosis, Molecular Classification, and Neoadjuvant Chemotherapy Response Evaluation
NCT06908291Breast Masses, Breast Cancer, Breast Cancer Treated with Neoadjuvant Chemotherapy
Peking Union Medical College Hospital
Not applicable
500
Beijing
2023-06-12
Recruiting
First Affiliated Hospital of Guangxi Medical University
Not applicable
190
Fuzhou, Guangzhou, Huizhou, Guilin, Liuzhou, Nanning, Wuzhou, Yulin
2023-06-12
Recruiting
Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients
NCT05912816Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation, HER-2 ADC, PD-1antibody
DrugsDisitamab Vedotin·Tislelizumab
RenJi Hospital
Phase 2
20
Shanghai
2023-06-10
Recruiting
Sun Yat-sen University
Phase 3
126
Guangdong
2023-06-10
Recruiting
Shanghai Zhongshan Hospital
Not applicable
102
Shanghai
2023-06-10
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
216
Guangzhou
2023-06-10
Recruiting
Revascularization Effect on CSVD Burden in Carotid Artery Stenosis
NCT06031610Carotid Artery Stenosis, Cerebral Small Vessel Diseases
Zhejiang Provincial People's Hospital
Observational
1,000
Hangzhou
2023-06-10
Recruiting
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
NCT05740956Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostatic Cancer
DrugHS-10502
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
318
Beijing
2023-06-09
Active, closed
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1/2
84
Beijing, Chengdu, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang, Wuhan
2023-06-09
Recruiting
Cohort Study of Chronic Heart Failure
NCT05960890Heart Failure
Jiangsu Taizhou People's Hospital
Not applicable
1,000
Taizhou
2023-06-08
Recruiting
Hansoh BioMedical R&D Company
Phase 2
170
Beijing, Changsha, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin, Zhengzhou
2023-06-08
Recruiting
RemeGen Co., Ltd.
Phase 2
85
Beijing
2023-06-08
Recruiting
Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders.
NCT05774288Patent Foramen Ovale, Cryptogenic Stroke
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
244
Beijing, Guangzhou, Meizhou, Changsha, Changchun, Shenyang, Jinan, Kunming
2023-06-08
Recruiting
Hoffmann-La Roche
Phase 3
420
Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang
2023-06-07
Recruiting
Fudan University
Phase 3
1,406
Shanghai
2023-06-07
Recruiting
Children's Hospital of Fudan University
Not applicable
240
Shanghai
2023-06-07
Active, closed
Yongxu Jia
Phase 2
37
Zhengzhou
2023-06-07
Recruiting
Guangzhou JOYO Pharma Co., Ltd
Phase 2/3
210
Beijing
2023-06-06
Recruiting
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
NCT06302062Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy
DrugsAldesleukin·Serplulimab·Cyclophosphamide
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
23
Guangzhou
2023-06-06
Active, closed
Eli Lilly and Company
Phase 3
3,127
Hefei, Beijing, Chongqing, Shenzhen, Haikou, Harbin, Luoyang Shi, Zhengzhou
2023-06-05
Recruiting
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT05303519Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3
DrugSafusidenib
Nuvation Bio Inc.
Phase 3
365
Beijing, Fuzhou, Guangzhou, Changsha, Shanghai, Chengdu
2023-06-05
Recruiting
The Pathogenesis and Prognostic Factors of Lymphoma
NCT06203652Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
Shanghai Zhongshan Hospital
Observational
2,000
Shanghai
2023-06-05
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
622
Chengdu, Chongqing, Guangzhou, Jinan, Xi'an, Zhengzhou
2023-06-05
Recruiting
West China Hospital
Not applicable
276
Sichuan
2023-06-05
Recruiting
Sound Biopharmaceuticals Ltd.
Phase 1
44
Beijing, Chongqing, Chengdu
2023-06-05
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Observational
100
Tianjin
2023-06-05
Recruiting
Yi Yang
Observational
3,000
Changchun
2023-06-05
Recruiting
Peking Union Medical College Hospital
Observational
3,705
Beijing
2023-06-04
Active, closed
Shanghai Eye Disease Prevention and Treatment Center
Not applicable
236
Shanghai
2023-06-03
Active, closed
Guangdong Raynovent Biotech Co., Ltd
Phase 2
180
Guangzhou
2023-06-03
Active, closed
GeneCradle Inc
Phase 1/2
16
Beijing, Changsha, Hangzhou, Zhengzhou
2023-06-02
Recruiting
Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis
NCT05882708Sepsis, Ivabradine, Hemodynamics, Heart Rate Control
DrugIvabradine
Second Affiliated Hospital of Guangzhou Medical University
Phase 4
172
Guangzhou
2023-06-01
Active, closed
ArriVent BioPharma, Inc.
Phase 3
398
Beijing, Meizhou, Xuhui, Hangzhou, Cangzhou, Shushan, Zhengzhou, Changchun
2023-06-01
Active, closed
Health Belief Model-Based Survey on Breast Self-Examination Awareness and Practice Among Community-Dwelling Middle-Aged and Older Women
NCT07149636Breast Neoplasms, Breast Self-Examination, Cancer Screening, Health Belief Model
Peking Union Medical College Hospital
Observational
3,000
Beijing
2023-06-01
Recruiting
Peking Union Medical College Hospital
Phase 2
81
Beijing
2023-06-01
Recruiting
Hoffmann-La Roche
Phase 3
200
Wuhan, XI 'an City, Shaanxi Province, Shanghai, Beijing, Changchun, Chengdu, Guangzhou, Hangzhou
2023-06-01
Recruiting
Fudan University
Phase 3
606
Shanghai
2023-06-01
Active, closed
Xiangya Hospital of Central South University
Not applicable
250
Changsha
2023-06-01
Recruiting
Ruijin Hospital
Phase 2
86
Shanghai
2023-06-01
Recruiting
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
1,000
Shanghai
2023-06-01
Active, closed
Effect of IOP Lowering on Progressive HM
NCT05850936High Myopia, Intraocular Pressure
Sun Yat-sen University
Not applicable
152
Guangzhou
2023-06-01
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 3
104
Nanjing
2023-06-01
Recruiting
Wenjin Yin
Not applicable
86
Shanghai
2023-06-01
Active, closed
Biotheus Inc.
Phase 2
50
Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan
2023-06-01
Recruiting
Fudan University
Phase 2
1,008
Shanghai
2023-06-01
Recruiting
Peking University People's Hospital
Observational
120
Beijing
2023-06-01
Recruiting
TCRCure Biopharma Ltd.
Phase 1
18
Chongqing
2023-06-01
Recruiting
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
73
Beijing
2023-06-01
Active, closed
MRD in High-risk EBC
NCT06566729Breast Cancer
Shanghai Jiao Tong University School of Medicine
Observational
125
Shanghai
2023-06-01
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
24
Nanjing
2023-06-01
Recruiting
The Effects of Uterine Fibroids on Pregnancy in Women
NCT06020924Female Infertility, Uterine Fibroid
Wenwen Wang
Observational
1,658
Wuhan
2023-06-01
Recruiting
RenJi Hospital
Observational
45
Shanghai
2023-06-01
Recruiting
Dushu Lake Hospital Affiliated to Soochow University
Phase 1/2
25
Suzhou
2023-06-01
Recruiting
Shandong Cancer Hospital and Institute
Phase 2
31
Nanchang, Jinan
2023-06-01
Recruiting
Fudan University
Phase 3
766
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-01
Recruiting
Ruijin Hospital
Phase 2
43
Shanghai
2023-06-01
By invitation
West China Hospital
Not applicable
100
Chengdu
2023-06-01
Not yet open
Renmin Hospital of Wuhan University
Not applicable
1,644
Wuhan
2023-06-01
Recruiting
Fujian Medical University Union Hospital
Phase 3
76
Fuzhou
2023-06-01
Recruiting
Chinese PLA General Hospital
Observational
12,567
Beijing
2023-06-01
Recruiting
Peking Union Medical College Hospital
Observational
300
Beijing
2023-06-01
Recruiting
Effects of Digital Therapeutic in Whole Process Management of Lung Cancer
NCT06230445Application of Digital Therapeutic in Lung Cancer Whole Process Management
Sun Yat-sen University
Phase 3
900
Guangzhou
2023-06-01
Recruiting
Leflunomide for Idiopathic Pulmonary Hemosiderosis in Children
NCT05937191Idiopathic Pulmonary Hemosiderosis, Leflunomide
DrugLeflunomide
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2
34
Guangzhou
2023-06-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
37
Guangzhou
2023-06-01
Recruiting
Ruijin Hospital
Observational
332
Shanghai
2023-06-01
Active, closed
Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Phase 2
80
Beijing
2023-06-01
Recruiting
Shanghai Cell Therapy Group Co.,Ltd
Early Phase 1
12
Shanghai
2023-06-01
Recruiting
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
NCT05901428Hormone Receptor Positive HER-2 Negative Breast Cancer
DrugsEpirubicin·Docetaxel·Cyclophosphamide·Carboplatin
Fudan University
Phase 3
1,736
Shanghai
2023-06-01
Recruiting
Magnetocardiography in the Accurate Identification of Myocardial Infarction
NCT05896826Chest Pain, Acute Coronary Syndrome, Myocardial Infarction
Qilu Hospital of Shandong University
Observational
3,841
Jinan
2023-06-01
Recruiting
RenJi Hospital
Phase 3
488
Shanghai
2023-06-01
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
58
Shijiazhuang
2023-06-01
Not yet open
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
70
Guangzhou
2023-06
Recruiting
Chinese PLA General Hospital
Observational
750
Beijing
2023-06
Recruiting
Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
NCT05917431Unresectable Hepatocellular Carcinoma, Oligometastatic Disease
Peking University Cancer Hospital & Institute
Phase 2
39
Beijing
2023-06
Not yet open
Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer
NCT05802654Early Lung Cancer, Stereotactic Body Radiotherapy
Peking University Third Hospital
Not applicable
100
Beijing
2023-06
Recruiting
RenJi Hospital
Not applicable
120
Shanghai
2023-05-31
Recruiting
Shanghai Zhongshan Hospital
Not applicable
200
Shanghai
2023-05-31
Active, closed
Amgen
Phase 3
509
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Shijiazhuang, Harbin
2023-05-31
Recruiting
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05729646Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency
DrugsToripalimab·Oxaliplatin
Yu jiren
Phase 2
90
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-05-31
Active, closed
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05715931Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer
DrugsFLOT·Trastuzumab·Toripalimab
Yu jiren
Phase 2
30
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-05-30
Recruiting
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
NCT05930210Diabetic Foot Ulcer, Foot Ulcer, Diabetes Mellitus, Wound
Energenesis Biomedical Co., Ltd.
Phase 3
230
2023-05-30
Recruiting
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma
NCT07644897Melanoma, Immune-related Adverse Event, Immune Checkpoint Inhibitor
Sun Yat-sen University
Phase 2
55
Guangzhou, Shenzhen
2023-05-30
Recruiting
The First Affiliated Hospital of Xiamen University
Observational
100
Xiamen
2023-05-30
By invitation
Abbisko Therapeutics Co, Ltd
Phase 2
64
Beijing, Chongqing, Fuzhou, Guangzhou, Zhujiang, Wuhan, Hangzhou, Suzhou
2023-05-30
Recruiting
SG1906 for CLDN18.2-Positive Solid Tumors
NCT05857332Locally Advanced Unresectable or Metastatic Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1
60
Beijing, Xiamen, Guangzhou, Zhengzhou, Shenyang, Taiyuan, Hangzhou
2023-05-30
Recruiting
Istituto Giannina Gaslini
Observational
2,000
Nanjing
2023-05-30
Recruiting
Beijing Chest Hospital
Phase 4
292
Beijing
2023-05-29
Recruiting
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 1
60
Beijing
2023-05-29
Recruiting
A Multi-domain Lifestyle Intervention Among Aged Community-residents in Zhejiang, China
NCT05886114Cognitive Impairment, Alzheimer Disease, Vascular Cognitive Impairment, Dement
Zhejiang University
Not applicable
1,200
Hangzhou
2023-05-28
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
126
Guli, Yiwu, Dongyang, Hangzhou, Jinhua, Lanxi
2023-05-28
Recruiting
Peking Union Medical College Hospital
Not applicable
2,478
Beijing, Changchun, Changsha, Changzhou, Chengdu, Dalian, Dongying, Guiyang
2023-05-26
Active, closed
A Study of MHB036C for Advanced Solid Tumor
NCT06373406Advanced Solid Tumor
DrugMHB036C
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
200
Shanghai
2023-05-26
Active, closed
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
453
Guangzhou
2023-05-25
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Observational
2,000
Shanghai
2023-05-25
Recruiting
Akeso
Phase 2
78
Beijing, Guangzhou, Wuhan, Jinan, Shanghai, Hangzhou
2023-05-25
Recruiting
Xiangya Hospital of Central South University
Observational
400
Guangzhou, Chenzhou, Hengyang
2023-05-25
Recruiting
Dongzong Cardiovascular Bio-imaging Registry Study
NCT06894095Cardiovascular Diseases, Multi-omics, Living Environments, Pulmonary-cardiovascular Imaging
Jinling Hospital, China
Observational
50,000
Nanjing, Suqian, Zhenjiang
2023-05-24
Recruiting
First Affiliated Hospital, Sun Yat-Sen University
Phase 4
194
Guangzhou
2023-05-24
Recruiting
Guangzhou JOYO Pharma Co., Ltd
Phase 2
35
Changsha
2023-05-24
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
3
Tianjin
2023-05-23
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
25
Tianjin
2023-05-23
Recruiting
China-Japan Friendship Hospital
Phase 4
340
Beijing
2023-05-23
Recruiting
Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients
NCT05494502Breast Neoplasms, Mastectomy, Nerve Block, Dexmedetomidine
Peking University First Hospital
Not applicable
1,206
Beijing
2023-05-23
Recruiting
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Early Phase 1
16
Shanghai
2023-05-23
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 4
25
Tianjin
2023-05-22
Recruiting
Second Affiliated Hospital of Wenzhou Medical University
Not applicable
40
Wenzhou
2023-05-20
Recruiting
Sun Yat-sen University
Phase 3
424
Guangzhou
2023-05-20
Recruiting
Henan Cancer Hospital
Observational
200
Zhengzhou
2023-05-20
Recruiting
Pfizer
Phase 3
318
Hefei, Beijing, Dongguan, Guangzhou, Cangzhou, Changsha, Nanjing, Nanchang
2023-05-20
Recruiting
Gene Therapy for Diabetic Macular Edema
NCT05916391Diabetic Macular Edema
Frontera Therapeutics
Phase 1
18
Tianjin
2023-05-19
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
174
Hangzhou
2023-05-18
Recruiting
Chinese University of Hong Kong
Phase 4
594
Guangzhou, Shenzhen, Yangjiang, Zhuhai, Hong Kong
2023-05-18
By invitation
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
NCT05859997Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
DrugBRL-301
Bioray Laboratories
Not applicable
15
Shanghai
2023-05-17
Active, closed
Biotheus Inc.
Phase 2
31
Chongqing, Fuzhou, Harbin, Zhengzhou, Jingzhou, Wuhan, Changsha, Yongzhou
2023-05-17
Recruiting
Novlead Inc.
Not applicable
16
Nanjing
2023-05-17
Recruiting
Sun Yat-sen University
Phase 2
53
Guangzhou
2023-05-17
Recruiting
Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study
NCT05860400Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis, Coronary Artery Disease Progression
Peking Union Medical College Hospital
Observational
39
Beijing
2023-05-17
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
36
Hangzhou
2023-05-16
Recruiting
Takeda
Phase 3
240
Beijing, Zhengzhou, Changsha, Shanghai, Hangzhou
2023-05-16
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
230
Hefei, Beijing, Xiamen, Xinxiang, Zhengzhou, Huai'an, Shanghai, Hangzhou
2023-05-16
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 2
30
Huai'an, Nanchang, Shanghai, Guangzhou
2023-05-15
Recruiting
Peking Union Medical College Hospital
Observational
235
Beijing
2023-05-15
Recruiting
Zhejiang University
Phase 2
49
Hangzhou
2023-05-15
Active, closed
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
35
Guangzhou
2023-05-15
Recruiting
Shandong Provincial Hospital
Observational
30
Jinan
2023-05-15
Recruiting
LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer
NCT05923255Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer
Zhejiang University
Not applicable
568
Bengbu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha
2023-05-14
Active, closed
Peking University Third Hospital
Not applicable
80
Beijing
2023-05-12
Recruiting
Pilot Study of AuTNA I
NCT05853107Retinitis Pigmentosa
Eye & ENT Hospital of Fudan University
Not applicable
7
Shanghai
2023-05-12
Recruiting
Ton-Bridge Medical Tech. Co., Ltd
Not applicable
200
Luoyang, Wuhan, Nanjing, Nanchang, Changchun, Dalian, Baotou, Kunming
2023-05-11
Recruiting
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 3
242
Shanghai
2023-05-11
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
62
Wuhan
2023-05-11
Recruiting
RenJi Hospital
Early Phase 1
18
Shanghai
2023-05-11
Recruiting
HBsAg Declined Patients Follow-up Study
NCT05977283Hepatitis B, Hepatitis B, Chronic
Nanfang Hospital, Southern Medical University
Observational
100
Guangzhou
2023-05-11
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
60
Beijing
2023-05-11
Active, closed
Sun Yat-sen University
Phase 2
30
Guangzhou
2023-05-10
Recruiting
Intensive Treatment on Periodontitis in Aortic Stenosis
NCT06587971Aortic Valve Stenosis, Periodontitis
China National Center for Cardiovascular Diseases
Not applicable
920
Beijing
2023-05-10
Recruiting
Fujian Cancer Hospital
Phase 2/3
130
Fuzhou
2023-05-10
Recruiting
Acute Ischemic Stroke EndoVascular Therapy: a Multicenter REGISTRY Study
NCT05864638Acute Ischemic Stroke, Large Vessel Occlusion, Thrombectomy, Thrombosis
Changhai Hospital
Observational
10,000
Shanghai
2023-05-10
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
480
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning
2023-05-10
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
NCT06565689Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
DrugYK012
Excyte Biopharma Ltd
Phase 1
48
Beijing
2023-05-09
Recruiting
Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy
NCT05839314Nephropathy, Glomerular Diseases, Idiopathic Membranous Nephropathy
DrugHuaier
Chinese PLA General Hospital
Phase 4
480
Beijing
2023-05-09
Recruiting
Weijia Fang, MD
Phase 2
30
Hangzhou
2023-05-08
Recruiting
Liling Zhang
Phase 2
36
Wuhan
2023-05-08
Active, closed
Akeso
Phase 1/2
170
Harbin
2023-05-08
Active, closed
Sun Yat-sen University
Phase 2
32
Guangzhou
2023-05-08
Active, closed
Gilead Sciences
Phase 3
654
Anhui, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fujian, Fuzhou
2023-05-08
Active, closed
Shanghai Chest Hospital
Observational
305
Hefei, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Jinan, Shanghai
2023-05-08
Active, closed
AstraZeneca
Phase 3
37
Beijing, Chongqing, Yangzhou, Zhengzhou
2023-05-08
Recruiting
First Affiliated Hospital of Guangxi Medical University
Phase 1
5
Nanning
2023-05-08
Recruiting
Keymed Biosciences Co.Ltd
Phase 2
70
Beijing
2023-05-08
Active, closed
Westlake University
Observational
237
Hangzhou
2023-05-08
Recruiting
Statins for Treatment of Primary Intracerebral Hemorrhage
NCT07088250Cerebrovascular Disorders, Intracranial Hemorrhages, Intracranial Hemorrhage, Intracerebral Haemorrhage
The Second Hospital of Anhui Medical University
Not applicable
264
Anqing, Fuyang, Hefei, Huainan, Lu'an, Suzhou, Harbin, Kaifeng
2023-05-06
Recruiting
Shanghai Institute of Hypertension
Not applicable
10,000
Shanghai
2023-05-06
Active, closed
The Effect of Remote Ischemic Preconditioning on Myocardial Injury After Noncardiac Surgery
NCT05733208Myocardial Injury, Non-cardiac Surgery, Remote Ischemic Preconditioning
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
766
Guangzhou
2023-05-06
Recruiting
West China Hospital
Not applicable
304
Chengdu
2023-05-05
Active, closed
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
63
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Fuxin, Shenyang
2023-05-05
Recruiting
Chen Wen
Observational
2,650
Yuncheng
2023-05-05
Recruiting
Gongji Pregnancy Endorine Cohort Study
NCT07125885Gestatiaonl Diabetes Mellitus, Thyroid Disease Pregnancy, Hyperglycemia in Pregnant Diabetic Patients
Shanghai General Hospital, China
Observational
3,000
Shanghai
2023-05-05
Recruiting
Binhui Biopharmaceutical Co., Ltd.
Phase 1
12
Wuhan
2023-05-05
Recruiting
Zhejiang Cancer Hospital
Phase 2
20
Hangzhou, Hanzhou
2023-05-05
Recruiting
Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords
NCT05688488Glottic Web of Larynx, Laryngeal Stenosis, Glottic Carcinoma, Laryngeal Leucoplakia
DrugMitomycin C
Eye & ENT Hospital of Fudan University
Phase 1/2
100
Shanghai
2023-05-05
Active, closed
Novartis Pharmaceuticals
Phase 2
63
Wuhan, Nanjing, Shenyang, Xian, Chengdu, Hangzhou, Beijing, Guangzhou
2023-05-05
Active, closed
CRUSTAL Study in China
NCT05828186Coronary Artery Disease, Calcification
First Affiliated Hospital of Guangxi Medical University
Observational
200
Liuzhou, Yulin, Nanjing, Guilin, Guiping
2023-05-04
Recruiting
Avatrombopag for Platelet Recovery Post-UCBT in Patients With Bone Marrow Failure Disease
NCT05823376Platelet Recovery After Umbilical Cord Blood Transplantation
DrugAvatrombopag
Anhui Provincial Hospital
Observational
40
Hefei
2023-05-04
Recruiting
Renmin Hospital of Wuhan University
Observational
10
Wuhan
2023-05-04
Recruiting
RC48-ADC in HER2-low Advanced Breast Cancer
NCT05831878Advanced Breast Cancer
DrugDisitamab Vedotin
RenJi Hospital
Not applicable
36
Shanghai
2023-05-04
Recruiting
Henan Cancer Hospital
Phase 2
610
Zhengzhou
2023-05-03
Recruiting
Frontline of ASCT in High-risk DLBCL
NCT05831865Diffuse Large B Cell Lymphoma
Peking University People's Hospital
Observational
175
Beijing
2023-05-03
By invitation
The Hong Kong Polytechnic University
Not applicable
2,160
Hong Kong
2023-05-02
Recruiting
Ruijin Hospital
Phase 4
8
Shanghai
2023-05-01
Recruiting
Study on Heart Failure with Preserved Ejection Fraction with Qishen Granules
NCT06377761Heart Failure with Preserved Ejection Fraction
Guangdong Provincial Hospital of Traditional Chinese Medicine
Not applicable
80
Guangzhou
2023-05-01
Not yet open
Xin Cai
Phase 2
31
Shanghai
2023-05-01
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
260
Hangzhou
2023-05-01
Recruiting
Chinese PLA General Hospital
Phase 2
10
Beijing
2023-05-01
Recruiting
Li An
Observational
365
Beijing
2023-05-01
Active, closed
Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
NCT07018427Breast Neoplasms, Triple Negative Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Breast Cancer
DrugSacituzumab Govitecan
Peking University Cancer Hospital & Institute
Observational
70
Beijing
2023-05-01
Active, closed
Drug Induced Liver Disease Study Group
Observational
2,000
Shanghai
2023-05-01
Recruiting
Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction
NCT05892042ST-segment Elevation Myocardial Infarction (STEMI), Left Ventricular Thrombus
DrugRivaroxaban
Jilin University
Not applicable
320
Changchun
2023-05-01
Recruiting
Beijing Friendship Hospital
Observational
407
Beijing
2023-05-01
Active, closed
First Affiliated Hospital of Chongqing Medical University
Not applicable
60
Chongqing
2023-05-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
120
Hangzhou
2023-05-01
Active, closed
RenJi Hospital
Phase 2
40
Shanghai
2023-05-01
Recruiting
The University of Hong Kong
Not applicable
100
Shanghai
2023-05-01
Recruiting
Shanghai University of Traditional Chinese Medicine
Not applicable
367
Shanghai
2023-05-01
Not yet open
Fudan University
Phase 2
47
Shanghai
2023-05-01
Recruiting
Xuanwu Hospital, Beijing
Observational
458
Beijing
2023-05-01
Active, closed
Shanghai Changzheng Hospital
Phase 2
30
Shanghai
2023-05-01
Recruiting
Hebei Medical University Fourth Hospital
Not applicable
20
Shijiazhuang
2023-05-01
Active, closed
The Affiliated Hospital of Xuzhou Medical University
Observational
500
Xuzhou
2023-05-01
Recruiting
Fujian Medical University
Observational
194
Fuzhou
2023-05-01
Recruiting
Second Xiangya Hospital of Central South University
Observational
200
Changsha
2023-05-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
40
Hangzhou
2023-05-01
Not yet open
Suzhou Puhe Pharmaceutical Technology Co., LTD
Phase 3
350
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou
2023-05-01
Recruiting
Sun Yat-sen University
Phase 3
244
Guangzhou
2023-05-01
Recruiting
Juan Kang
Observational
800
Chongqing
2023-05-01
Recruiting
Tongji Hospital
Phase 2
300
Wuhan
2023-05-01
Recruiting
Fujian Medical University Union Hospital
Not applicable
537
Fuzhou
2023-05-01
Recruiting
Nanfang Hospital, Southern Medical University
Observational
2,592
Fuzhou, Dongguan, Guangzhou, Heyuan, Huizhou, Haikou, Changsha, Hengyang
2023-05-01
Recruiting
Beijing Tongren Hospital
Phase 3
272
Beijing
2023-05-01
Not yet open
Chongqing University Cancer Hospital
Phase 2
36
Chongqing
2023-05-01
Recruiting
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
94
Shanghai
2023-05-01
Recruiting
Anhui Medical University
Not applicable
40
Hefei
2023-05-01
Recruiting
First Affiliated Hospital of Zhejiang University
Observational
80
Hangzhou
2023-05-01
Recruiting
First Affiliated Hospital, Sun Yat-Sen University
Phase 3
474
Guangzhou
2023-05
Not yet open
Peking Union Medical College Hospital
Phase 2
74
Beijing
2023-05
Not yet open
Real World Study of Linperlisib for Lymphoma Treatment
NCT05863871Focus on the Lymphoma Including B/T-cell Lymphoma
DrugLinperlisib
Ruijin Hospital
Observational
1,000
Shanghai, Tianjin
2023-05
Not yet open
Shanghai Zhongshan Hospital
Not applicable
4,648
Shanghai
2023-05
Recruiting
Sun Yat-sen University
Phase 3
540
Guangzhou, Guiyang, Harbin, Zhengzhou, Wuhan, Nanchang, Dalian, Shanghai
2023-04-30
Recruiting
RenJi Hospital
Observational
172
Shanghai
2023-04-30
Recruiting
Lenvatinib for Advanced Bone and Soft Tissue Sarcoma
NCT05617859Effectiveness, Sexuality
DrugLenvatinib
Henan Cancer Hospital
Phase 2
60
Zhengzhou
2023-04-30
Recruiting
Zhejiang University
Phase 1/2
30
Hangzhou
2023-04-30
Active, closed
Study of CT071 Injection in RRMM or PPCL
NCT05838131Multiple Myeloma, Primary Plasma Cell Leukemia
Shanghai Changzheng Hospital
Early Phase 1
20
Shanghai
2023-04-28
Active, closed
XIANG YANQUN
Phase 3
166
Guangzhou
2023-04-28
Active, closed
RemeGen Co., Ltd.
Phase 3
318
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou
2023-04-28
Recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2/3
600
Beijing
2023-04-28
Recruiting
Efficacy and Safety of Head Acupuncture After Mechanical Thrombectomy for Acute Ischemic Stroke
NCT05561088Acupuncture, Acute Ischemic Stroke, Mechanical Thrombectomy
Xi'an No.3 Hospital
Not applicable
272
Xi'an
2023-04-27
Recruiting
Yuehui Yin
Observational
480
Chongqing
2023-04-27
Active, closed
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
NCT05804045Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
DrugPimicotinib
Abbisko Therapeutics Co, Ltd
Phase 3
94
Bengbu, Beijing, Fuzhou, Guangzhou, Guiyang, Zhengzhou, Enshi, Wuhan
2023-04-27
Recruiting
Ruijin Hospital
Early Phase 1
54
Qionghai
2023-04-26
Recruiting
GONGCHU Biotechnology Co., Ltd
Phase 1
21
Zhengzhou
2023-04-26
Recruiting
Fudan University
Phase 3
134
Shanghai
2023-04-25
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
213
Haerbin
2023-04-25
Recruiting
Peking Union Medical College Hospital
Observational
150
Beijing
2023-04-25
Recruiting
Xuanwu Hospital, Beijing
Observational
50,000
Beijing
2023-04-25
Recruiting
Bioray Laboratories
Phase 1
18
Wuhan, Tianjin, Hangzhou
2023-04-25
Active, closed
AstraZeneca
Phase 2
294
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Harbin, Nanning, Shanghai
2023-04-24
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2/3
374
Fuzhou, Guangzhou, Guiyang, Anyang, Luoyang, Pingxiang, Changchun, Yinchuan
2023-04-24
Active, closed
Long COVID and Its Associations With Health Outcomes in Older Adults
NCT05825651Long COVID, COVID-19 Pandemic, Elderly Infection, Vaccine Reaction
Peking University
Observational
11,527
Kunming
2023-04-24
Recruiting
Betta Pharmaceuticals Co., Ltd.
Phase 1
82
Beijing, Baoding, Harbin, Wuhan, Changsha, Changchun, Jinan, Taizhou
2023-04-24
Recruiting
Chinese Academy of Medical Sciences, Fuwai Hospital
Early Phase 1
210
Beijing, Shanghai, Hangzhou
2023-04-24
Recruiting
Qilu Hospital of Shandong University
Phase 2
50
Jinan
2023-04-23
Recruiting
First Affiliated Hospital Xi'an Jiaotong University
Observational
1,000
Xi'an
2023-04-23
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2023-04-21
Active, closed
Zhejiang Cancer Hospital
Phase 2
89
Hangzhou
2023-04-21
Recruiting
shifeng Lou
Not applicable
160
Chongqing
2023-04-20
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
76
Shanghai
2023-04-20
Recruiting
Guangzhou Gloria Biosciences Co., Ltd.
Phase 3
424
Shanghai
2023-04-20
Recruiting
Peking University Third Hospital
Phase 2
20
Beijing
2023-04-20
Active, closed
Klus Pharma Inc.
Phase 2
356
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-04-19
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
6
Tianjin
2023-04-19
Recruiting
ZHOU FANGJIAN
Phase 3
298
Beijing, Guangzhou, Hefei, Shanghai, Sichuan, Tianjin, Zhengzhou
2023-04-19
Recruiting
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2
70
Guangzhou, Chengdu
2023-04-19
Active, closed
Clinical Trial of Mica
NCT05680415Latent Tuberculosis Infection
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Phase 4
6,800
Liuzhou
2023-04-19
Recruiting
Jiangsu Province Nanjing Brain Hospital
Not applicable
150
Nanjing
2023-04-19
Recruiting
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT06702995Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
DrugsMevrometostat·Xtandi·Enzalutamide
Evopoint Biosciences Inc.
Phase 1/2
307
Jinan, Shanghai
2023-04-19
Recruiting
Pfizer
Phase 2
48
Beijing, Guangzhou, Shanghai
2023-04-18
Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
DrugsPanitumumab·Folfox·Cetuximab·Nab-paclitaxel
Institut de Recherches Internationales Servier
Phase 1/2
554
Beijing, Jinan, Shanghai, Suzhou
2023-04-18
Active, closed
Regor Pharmaceuticals Inc.
Phase 1
40
Shanghai
2023-04-17
Active, closed
BeOne Medicines
Phase 2/3
178
Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang
2023-04-17
Recruiting
Sichuan Jishengtang Pharmaceutical Co., Ltd.
Phase 3
495
Beijing
2023-04-17
Recruiting
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Weill Medical College of Cornell University
Not applicable
2,300
Beijing, Changchun, Shanghai, Tianjin
2023-04-17
By invitation
Nanfang Li
Phase 4
8,000
Ürümqi
2023-04-16
Recruiting
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
100
Shanghai
2023-04-15
Active, closed
Tianjin Medical University General Hospital
Phase 1
11
Tianjin
2023-04-15
Recruiting
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
160
Guangzhou
2023-04-14
Recruiting
Akeso
Phase 1/2
87
Beijing
2023-04-14
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
118
Ningbo
2023-04-13
Active, closed
Hoffmann-La Roche
Phase 2
204
Beijing, Chengdu, Guangzhou, Shanghai
2023-04-13
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
154
Chongqing, Harbin
2023-04-13
Active, closed
TrEatment Approach in the Multimodal Era Registry
NCT05629052Chronic Thromboembolic Pulmonary Hypertension, CTEPH
International CTEPH Association
Observational
1,000
Beijing
2023-04-12
Recruiting
Immunotherapy with Autologous Tregs in T1DM
NCT06708780Type 1 Diabetes Mellitus
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1
20
Nanjing
2023-04-12
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
100
Nanjing
2023-04-12
Recruiting
Qilu Hospital of Shandong University
Phase 4
2,600
Bozhou, Chuzhou, Hefei, Beijing, Zunyi, Zhengzhou, Dalian, Xining
2023-04-12
Active, closed
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2023-04-12
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
148
Huizhou, Nanyang, Lianyungang, Weihai, Tianjin
2023-04-12
Recruiting
Cell Origin Biotech (Hangzhou) Co., Ltd.
Not applicable
2
Hangzhou, Linyi
2023-04-12
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
Beijing, Cangzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2023-04-11
Recruiting
Emergency PWAS in Respiratory Infectious Disease
NCT05336851Viral Infections, Bacterial Infections, Fungal Infections, Mixed Infection
The University of Hong Kong
Observational
2,000
Hong Kong
2023-04-11
Recruiting
China National Center for Cardiovascular Diseases
Phase 4
202
Beijing
2023-04-11
Recruiting
Nanfang Hospital, Southern Medical University
Phase 2
57
Guandong
2023-04-10
Recruiting
Fifth Affiliated Hospital, Sun Yat-Sen University
Not applicable
23
Zhuhai
2023-04-10
Recruiting
The First Affiliated Hospital of Xiamen University
Not applicable
30
Xiamen
2023-04-09
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 4
2,260
Nanjing, Changzhou, Chongqing, Dalian, Daqing, Dongguan, Fengcheng, Guangzhou
2023-04-08
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 2
188
Nanjing
2023-04-08
Recruiting
IVUS-guided DES Implantation in Coronary Calcification
NCT05800002Coronary Artery Disease
Nanjing First Hospital, Nanjing Medical University
Not applicable
864
Nanjing
2023-04-07
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
300
Beijing, Guangzhou, Luoyang, Hengshui, Daqing, Wuhan, Baotou, Huai'an
2023-04-06
Active, closed
Lepu Biopharma Co., Ltd.
Phase 2
238
Beijing, Chongqing, Fuzhou, Guangzhou, Maoming, Shantou, Shaoguan, Zhongshan
2023-04-06
Recruiting
Shanghai Miracogen Inc.
Phase 3
290
Beijing
2023-04-06
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
395
Shanghai
2023-04-06
By invitation
Sanofi
Phase 2
70
Tianjin
2023-04-05
Active, closed
Sanofi
Phase 2
118
Changsha, Guangzhou, Nanchang, Shenyang, Tianjin, Wuhan
2023-04-05
Recruiting
Lepu Biopharma Co., Ltd.
Phase 3
180
Shanghai
2023-04-04
Recruiting
Henan Cancer Hospital
Observational
300
Zhengzhou
2023-04-04
Recruiting
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
NCT05800340Non-Small Cell Lung Cancer, RET Driver Mutation, BRAF V600 Mutation, Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation
DrugsToripalimab·Nab-paclitaxel·Pemetrexed·Carboplatin
Guangdong Provincial People's Hospital
Phase 2
30
Guanzhou
2023-04-04
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
192
Guangzhou
2023-04-04
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
2023-04-04
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2023-04-04
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
368
Beijing, Chongqing
2023-04-04
Recruiting
Xijing Hospital
Phase 2
194
Xi'an
2023-04-03
Recruiting
Nanfang Hospital, Southern Medical University
Phase 4
7,188
Hefei, Huainan, Suzhou, Beijing, Chongqing, Foshan, Guangzhou, Zhongshan
2023-04-03
Active, closed
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
NCT05631899Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V, KRAS G12C
DrugsAbraxane·Ipilimumab·Cyclophosphamide
Chinese PLA General Hospital
Phase 1
9
Beijing
2023-04-03
Active, closed
Sanofi
Phase 2
999
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jingzhou
2023-04-03
Active, closed
Bayer
Phase 3
985
Beijing, Wuhan, Changsha, Nanjing, Shanghai, Chengdu, Tianjin, Hangzhou
2023-04-03
Recruiting
Corona Virus Disease 2019 Cohort Study
NCT06927622COVID-19 Pneumonia, COVID-19 Pandemic, COVID-19
Shandong University
Observational
1,000
Jinan
2023-04-01
Recruiting
Children's Hospital of Fudan University
Not applicable
60
Shanghai
2023-04-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 4
100
Guangzhou
2023-04-01
Recruiting
Peking University People's Hospital
Phase 2
38
Beijing
2023-04-01
Recruiting
Xiuping Ding
Phase 2
69
Jinan
2023-04-01
Not yet open
Sun Yat-sen University
Phase 3
132
Guangzhou
2023-04-01
Active, closed
fMRI Study of the Neural Mechanism of rTMS in the Treatment of Nicotine Dependence
NCT06762535Tobacco Use Disorder, Repetitive Transcranial Magnetic Stimulation
Tang-Du Hospital
Not applicable
50
Xi'an
2023-04-01
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
158
Hangzhou, Jiaxing, Jinhua, Ningbo, Yiwu
2023-04-01
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Observational
200
Nanjing
2023-04-01
Recruiting
The First Affiliated Hospital of Nanchang University
Not applicable
20
Nanchang
2023-04-01
Recruiting
The First Affiliated Hospital of University of Science and Technology of China
Not applicable
40
Hefei
2023-04-01
Active, closed
Hubei Cancer Hospital
Observational
60
Wuhan
2023-04-01
Not yet open
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
103
Nanjing, Nantong
2023-04-01
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
116
Guangzhou
2023-04-01
Recruiting
Peking Union Medical College Hospital
Not applicable
42
Beijing
2023-04-01
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3
366
Guangzhou
2023-04-01
Recruiting
Sir Run Run Shaw Hospital
Phase 3
108
Hangzhou
2023-04-01
Not yet open
Effect of Incentive Integrated E-IBD Chronic Disease Management Model on the Quality of Life in IBD Patients
NCT05719766Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
200
Hangzhou, Huzhou, Shanghai, Shaoxing
2023-04-01
Recruiting
Fudan University
Phase 3
634
Shanghai
2023-04-01
Recruiting
A Study of TIL in Advanced Solid Tumors (DFGD)
NCT06488950Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy
DrugEngineering Tumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Early Phase 1
30
Shanghai
2023-04-01
Not yet open
Shanghai JMT-Bio Inc.
Phase 3
146
Beijing
2023-04
Not yet open
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
38
Beijing
2023-04
Not yet open
Second Xiangya Hospital of Central South University
Observational
50
Changsha
2023-04
Not yet open
A Study of KM501 in Patients With Solid Tumors
NCT05804864Advanced Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
96
Tianjin
2023-04
Recruiting
Shanghai Hongdian Medical CO., LTD
Not applicable
180
Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Harbin, Zhengzhou, Zhenzhou
2023-03-31
Recruiting
Fudan University
Phase 3
390
Shanghai
2023-03-31
Recruiting
Henan Cancer Hospital
Phase 2
150
Zhengzhou
2023-03-31
Recruiting
Shanghai Tong Ren Hospital
Phase 2
58
Shanghai
2023-03-31
Recruiting
AstraZeneca
Phase 3
4,300
Baoding, Beijing, Changchun, Changsha, Chengdu, Chifeng, Dalian, Foshan
2023-03-31
Recruiting
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
NCT05759793Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia
DrugCar-T
Nanjing IASO Biotechnology Co., Ltd.
Phase 1
12
Shanghai
2023-03-30
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
1,946
Beijing, Guangzhou, Suining
2023-03-30
Recruiting
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
NCT05749588Triple-negative Breast Cancer
DrugCamrelizumab
Fudan University
Phase 2
120
Shanghai
2023-03-30
Recruiting
TransThera Sciences (Nanjing), Inc.
Phase 1
37
Nanjing
2023-03-30
Active, closed
PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI
NCT05457582Acute Coronary Syndrome, Hyperlipidemias, Percutaneous Coronary Intervention, Cardiovascular Events
DrugHigh-intensity statin
Nanjing First Hospital, Nanjing Medical University
Not applicable
1,212
Nanjing
2023-03-30
Active, closed
The First Affiliated Hospital of Bengbu Medical University
Early Phase 1
15
Bengbu
2023-03-30
Recruiting
Peking Union Medical College Hospital
Not applicable
40
Beijing
2023-03-30
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2023-03-29
Recruiting
Peking University Cancer Hospital & Institute
Phase 3
472
Beijing
2023-03-29
Recruiting
China Medical University Hospital
Observational
304
2023-03-29
Recruiting
China-Japan Friendship Hospital
Phase 4
336
Beijing, Baoding, Qinhuangdao, Gongyi, Yangzhou, Jining, Qingdao, Changzhi
2023-03-29
Recruiting
Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention
NCT04937699Acute Coronary Syndrome, Percutaneous Coronary Intervention
DrugAspirin
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
2,690
Hangzhou
2023-03-28
Recruiting
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
NCT06041776Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
Betta Pharmaceuticals Co., Ltd.
Phase 3
570
Beijing, Nanjing, Shanghai
2023-03-28
Recruiting
Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05768529Relapsed or Refractory Non-Hodgkin's Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2
100
Changsha, Suzhou, Shanghai
2023-03-28
Recruiting
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
NCT05718895Advanced/Metastatic Solid Tumors
DrugATG-022
Antengene Biologics Limited
Phase 1
156
Beijing, Chengdu, Fuzhou, Hefei, Jinan, Lanzhou, Qingdao, Shanghai
2023-03-27
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
220
Beijing, Chongqing, Fuzhou, Nanning, Harbin, Luoyang, Zhengzhou, Changsha
2023-03-27
Recruiting
China-Japan Friendship Hospital
Not applicable
100
Beijing
2023-03-27
Active, closed
Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women
NCT06776055Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN - Cervical Intraepithelial Neoplasia
Shanghai Zerun Biotechnology Co.,Ltd
Observational
5,372
Lingchuan, Quanzhou, Xing’an, Daming, Dingxing, Zhengding, Puyang, Wenquan
2023-03-27
Active, closed
Shanghai Vitalgen BioPharma Co., Ltd.
Phase 1
12
Shanghai
2023-03-27
Active, closed
Beijing Tongren Hospital
Not applicable
572
Beijing
2023-03-26
Active, closed
Shanghai Zerun Biotechnology Co.,Ltd
Observational
348
Hezhou
2023-03-25
Recruiting
LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD)
NCT05765370Atherosclerotic Cardiovascular Disease, Older Patients, LDL Cholesterol
China National Center for Cardiovascular Diseases
Not applicable
4,200
Beijing
2023-03-24
Recruiting
F573 for Injection for the Treatment of Liver Injury/Failure
NCT05689645Acute Liver Failure, Acute-On-Chronic Liver Failure
Beijing Continent Pharmaceutical Co, Ltd.
Phase 2
97
Beijing, Qingyuan, Shiyan, Huaihua, Pingxiang, Changchun, Binzhou, Heze
2023-03-24
Recruiting
A Study of XZB-0004 in Patients With Solid Tumors
NCT05772455Advanced Solid Tumor, NSCLC
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
128
Shanghai
2023-03-24
Active, closed
SeQuent ® Please CIS for the Treatment of INtracranial Atherosclerotic Stenosis
NCT06047964Stroke, Intracranial Atherosclerotic Stenosis
B. Braun Medical International Trading Company Ltd.
Not applicable
281
Beijing, Harbin, Nanyang, Changchun, Jining, Qingdao, Shanghai, Taiyuan
2023-03-23
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
9
Tianjin
2023-03-23
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
56
Shanghai
2023-03-23
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
Beijing, Changchun, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou
2023-03-23
Recruiting
Safety and Efficacy of Preoperative SBRT and Radical Surgery for Soft Tissue Sarcoma of Extremities
NCT06760221Soft Tissue Sarcoma, Stereotactic Body Radiotherapy, Surgery
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
20
Hangzhou
2023-03-23
Recruiting
Second Xiangya Hospital of Central South University
Observational
50
Changsha
2023-03-23
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 1
150
Shanghai
2023-03-22
Recruiting
Peking University Cancer Hospital & Institute
Phase 3
140
Beijing
2023-03-21
Active, closed
Wenzhou Gestational Diabetes Cohort
NCT05794152Gestational Diabetes Mellitus, Intrauterine Hyperglycemia, Birth Outcome, Adverse, Nutrition, Healthy
Westlake University
Not applicable
300
Wenzhou
2023-03-21
Recruiting
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 1
51
Beijing
2023-03-20
Recruiting
CEUS Improves the Diagnostic Performance of SRSS of Thyroid Carcinoma
NCT06146764Thyroid Nodule, Thyroid Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
800
Guangzhou
2023-03-18
Recruiting
Fudan University
Phase 3
223
Shanghai
2023-03-17
Recruiting
Fujian Medical University Union Hospital
Phase 2
214
Fuzhou
2023-03-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Beijing, Chongqing, Guangzhou, Guiyang, Haikou, Zhengzhou, Wuhan, Changsha
2023-03-16
Recruiting
Shengjing Hospital
Phase 2
65
Shenyang
2023-03-16
Recruiting
Teligene US
Phase 2
60
Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2023-03-16
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
400
Hanzhou
2023-03-15
Active, closed
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2
725
Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Ha’erbin, Hefei, Jinan
2023-03-15
Recruiting
The Efficacy of Compression/Ice Gloves/Socks in Patients With UTD1-induced Neuropathy.
NCT07638774Locally Advanced or Metastatic Breast Cancer
Fudan University
Not applicable
324
Shanghai
2023-03-15
Active, closed
Guangdong Provincial People's Hospital
Phase 2
48
Beijin, Guangzhou, Changsha
2023-03-15
Recruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
140
Wuhan, Nanjing, Taiyuan
2023-03-15
Recruiting
Effect of the Combined Programme on Perioperative Anaemia（CPPA）
NCT05353348Patient Blood Management, Cardiac Surgery, Iron Deficiency Anemia
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
110
Hangzhou
2023-03-15
Active, closed
AbbVie
Phase 3
520
Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-03-15
Recruiting
Sun Yat-sen University
Phase 3
232
Guangdong
2023-03-15
Recruiting
Stage II/III Colorectal Cancer Recurrence
NCT06314958Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Stage II, Colorectal Cancer Stage III
City of Hope Medical Center
Observational
400
Dalian
2023-03-15
Recruiting
The First Affiliated Hospital of Soochow University
Not applicable
43
Suzhou
2023-03-15
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
100
Shanghai
2023-03-14
Recruiting
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
NCT05760612Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab, RCB Classification 1-2
DrugTrastuzumab and Pertuzumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
300
Guangzhou
2023-03-14
Recruiting
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
NCT05671822HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
258
Shanghai
2023-03-14
Recruiting
Ascentage Pharma Group Inc.
Phase 1
105
Guangzhou
2023-03-13
Recruiting
BPH Global Registry
NCT05543200Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Société Internationale d'Urologie
Observational
7,500
Hangzhou
2023-03-13
Recruiting
China Children Eye Study
NCT05770661Axial Length, Myopia, Child Development
Shanghai Eye Disease Prevention and Treatment Center
Observational
30,000
Shanghai
2023-03-10
Recruiting
Clinical Observation of CABA System in the Treatment of End-stage Liver Disease With Inflammation
NCT05780190To Evaluate the Clinical Efficacy and Safety of the New ALSS
Qin Ning
Phase 4
40
Wuhan
2023-03-10
Recruiting
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
NCT05779917Pancreas Cancer, CAR-T Cell Therapy, Mesothelin, Solid Tumor, Adult
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2023-03-10
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Guangzhou, Nanning, Cangzhou, Shijiazhuang, Tangshan, Xingtai, Daqing, Harbin
2023-03-09
Recruiting
Chinese SLE Treatment And Research Group
Phase 4
40
Beijing
2023-03-09
Active, closed
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
219
Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Shenyang, Xi'an
2023-03-09
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
191
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhengzhou
2023-03-09
Recruiting
Sun Yat-sen University
Phase 2
55
Guangzhou
2023-03-09
Recruiting
OH2 Injection in Melanoma
NCT05868707Melanoma
DrugOH2
Binhui Biopharmaceutical Co., Ltd.
Phase 3
340
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin
2023-03-08
Recruiting
West China Hospital
Phase 2
200
Chengdu
2023-03-08
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 2
112
Zhengzhou
2023-03-08
Active, closed
Sichuan University
Phase 2
61
Chongqing, Shantou, Wuhan, Shenyang, Jinan, Shanghai, Chengdu, Guiyang
2023-03-07
Recruiting
KSX01-TCRT Injection Project in Solid Tumors
NCT05811975TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors
TCRx Therapeutics Co.Ltd
Early Phase 1
50
Nanning
2023-03-07
Recruiting
Regeneron Pharmaceuticals
Phase 3
202
2023-03-07
Recruiting
Evaluation of COVID-19 Immune Barrier and Reinfection Risk
NCT05774093COVID-19 Infection, Immunization; Infection
Sun Yat-sen University
Observational
300
Guangzhou
2023-03-06
Recruiting
Biomarker and Imaging Package Study in Immune Effector Cell-Associated Neurotoxicity Syndrome
NCT05643092Immune Effector Cell Associated Neurotoxicity Syndrome
zhang shoulong
Observational
50
Shijiazhuang
2023-03-06
Recruiting
Post-market European & Asian Registry to Evaluate the Minos™ Stent-Graft and Delivery System in Abdominal Aortic Aneurysm Treatment
NCT07674173Endovascular Repair of Infrarenal Abdominal Aortic Aneurysm Using Endovascular Stent Graft
Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd
Observational
200
Lanzhou, Meizhou, Shenzhen, Changsha, Xiangtan, Yueyang, Zibo, Binhai
2023-03-05
Active, closed
Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B)
NCT05512910Ischemic Stroke, Acute, Minocycline, Endovascular Treatment, Basilar Artery Occlusion
DrugMinocycline
Xijing Hospital
Phase 4
90
Xi'an
2023-03-04
Active, closed
Pfizer
Phase 3
624
Hefei, Beijing, Fuzhou Fujian, Foshan, Guangzhou, Nanning, Harbin, Luoyang
2023-03-03
Recruiting
Shanghai Institute Of Biological Products
Phase 1
36
Bengbu
2023-03-03
Recruiting
Sunshine Lake Pharma Co., Ltd.
Phase 3
324
Hanzhou
2023-03-03
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
100,000
Guanzhou
2023-03-02
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Guangzhou, Shantou, Haikou, Zhuzhou, Nanjing, Suzhou, Nanchang, Pingxiang
2023-03-02
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 2
188
Zhengzhou
2023-03-02
Recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
248
Shanghai
2023-03-02
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
37
Tianjin
2023-03-02
Active, closed
Energy Metabolism Profiles Over Weight-loss and Eating Responses
NCT05785221Homeostasis, Metabolism and Nutrition Disorder, Healthy, Obesity
Chinese Academy of Sciences
Not applicable
117
Hangzhou
2023-03-02
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 1
52
Zhengzhou, Shijiazhuang, Hangzhou, Beijing, Shanghai
2023-03-02
Recruiting
Study of Individualized, Precise and Standardized Cervical Open-door Surgery for Cervical Spinal Stenosis
NCT05786313Cervical Spinal Stenosis, Cervical Spinal Cord Injury, Individuation, Standardization
Xijing Hospital
Not applicable
500
Xi'an
2023-03-01
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
NCT06410651Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
53
Beijing
2023-03-01
Recruiting
Pingping Song
Phase 2
26
Jinan
2023-03-01
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
140
Hangzhou
2023-03-01
Active, closed
Qilu Hospital of Shandong University
Phase 2
59
Jinan, Qingdao, Yantai, Linyi
2023-03-01
Recruiting
Women's Hospital School Of Medicine Zhejiang University
Observational
5,000
Hangzhou, Taizhou
2023-03-01
Recruiting
Longitudinal Data Registry of Plasma Cell Dyscrasia
NCT06760052Multiple Myeloma and Other Plasma Cell Neoplasms
Shanghai Zhongshan Hospital
Observational
2,000
Shanghai
2023-03-01
Recruiting
Nova Therapeutics LLC
Phase 1
20
Beijing
2023-03-01
Recruiting
The Eye Hospital of Wenzhou Medical University
Observational
1,000,000
Guangzhou, Wenzhou
2023-03-01
Recruiting
Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
NCT05870969Carcinoma, Hepatocellular, Hepatitis C, Chronic, Hepatitis B, Chronic, Cirrhosis, Liver
Ruijin Hospital
Observational
20,000
Shanghai
2023-03-01
Recruiting
Qilu Hospital of Shandong University
Early Phase 1
220
Jinan
2023-03-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
100
Guangzhou
2023-03-01
Recruiting
Huazhong University of Science and Technology
Observational
100
Wuhan
2023-03-01
Recruiting
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Early Phase 1
6
Shanghai
2023-03-01
By invitation
FMT in Transplant-related Gastrointestinal Mucositis
NCT07622849Transplant-related Gastrointestinal Mucositis
DrugFecal microbiota
The First Affiliated Hospital of Soochow University
Observational
20
Suzhou
2023-03-01
Recruiting
Beijing Chao Yang Hospital
Observational
100
Beijing
2023-03-01
Recruiting
Surgical-imaging Research on Obesity (SIRO)
NCT06268262Overweight and Obesity
The Affiliated Hospital of Xuzhou Medical University
Observational
200
Xuzhou
2023-03-01
Active, closed
Tianjin Medical University Eye Hospital
Observational
100
Tianjin
2023-03-01
Recruiting
AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors
NCT06286267Phyllodes Breast Tumor, Artificial Intelligence, Multiomics, Prognostic Cancer Model
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
4,000
Guangzhou
2023-03-01
Recruiting
Combined Screening for Gastrointestinal Tumors
NCT06478030Gastrointestinal Tumors
Zhejiang Cancer Hospital
Observational
200,000
Jinhua, Ningbo
2023-03-01
Recruiting
Fudan University
Phase 2
25
Shanghai
2023-03-01
Active, closed
Fudan University
Phase 2
145
Shanghai
2023-03-01
Recruiting
Zhejiang University
Phase 3
190
Hangzhou
2023-03-01
Recruiting
First Affiliated Hospital of Harbin Medical University
Observational
400
Harbin
2023-03-01
Recruiting
A Clinical Study of Fundus OCTA for the Identification of CMD
NCT05743140Coronary Microvascular Disease
Peking University First Hospital
Observational
400
Beijing
2023-03-01
Recruiting
Xiaoping Luo
Observational
10,000
Wuhan
2023-03-01
Recruiting
Sun Yat-sen University
Phase 3
176
Hefei, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Nanchang, Shanghai
2023-03-01
Recruiting
Zhaoshen Li
Observational
100
Shanghai
2023-03-01
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2/3
60
Suzhou
2023-03-01
Recruiting
Zhejiang University
Not applicable
30
Hangzhou
2023-03-01
Recruiting
Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
NCT06788353Transarterial Chemoembolization, Systemic Therapy, Unresectable Hepatocellular Carcinoma
Sun Yat-sen University
Observational
500
Guangzhou
2023-03-01
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
NCT06429839Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
55
Beijing
2023-03-01
Recruiting
Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease
NCT07265544Liver Neoplasm, HBV Infection, Non-alcoholic Fatty Liver Disease NAFLD, Liver Fibrosis
Nanfang Hospital, Southern Medical University
Observational
240
Guangzhou
2023-03-01
Not yet open
Sun Yat-sen University
Phase 3
136
Guangzhou
2023-03
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
153
Hangzhou
2023-03
Recruiting
Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases
NCT05742425Unresectable Colon Cancer Peritoneal Metastases, PMMR/Ras/BRAF Wild-type
DrugSerplulimab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
30
Huzhou
2023-03
Recruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
96
Nanjing
2023-03
Not yet open
Peking University First Hospital
Observational
2,000
Hefei, Beijing, Chongqing, Zhengzhou, Shanghai
2023-03
Not yet open
Zhejiang University
Phase 3
38
Shanghai, Hangzhou, Ningbo
2023-03
Active, closed
Taizhou Hanzhong biomedical co. LTD
Phase 3
190
Bengbu, Fuyang, Hefei, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou
2023-02-28
Active, closed
Novartis Pharmaceuticals
Phase 2
33
Changchun, Tianjin
2023-02-28
Not yet open
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
44
Wuhan
2023-02-28
Recruiting
The Efficacy of Vosevi in Treating DAA-experienced Patients
NCT06180590Chronic Hepatitis C, Medication Reaction
The Third Affiliated Hospital of Guangzhou Medical University
Observational
200
Guangzhou
2023-02-28
Recruiting
Cuibai Wei，Clinical Professor
Observational
900
Beijing
2023-02-28
Recruiting
Ascentage Pharma Group Inc.
Phase 1/2
100
Guangzhou, Wuhan, Tianjin
2023-02-28
Active, closed
LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
NCT06198413Neovascular Age-Related Macular Degeneration
Innostellar Biotherapeutics Co.,Ltd
Phase 1
12
Hefei, Hangzhou, Shanghai
2023-02-27
Recruiting
Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors
NCT05847855Pancreatic Neuroendocrine Tumor, Solid Pancreatic Neoplasms
Fudan University
Observational
1,000
Shanghai, Chengdu
2023-02-27
Not yet open
Renmin Hospital of Wuhan University
Not applicable
867
Jiangmen, Wuhan
2023-02-26
Active, closed
AR Training in Adults With Unilateral Amblyopia
NCT06704737Amblyopia Unilateral, Amblyopia Functional
Eye & ENT Hospital of Fudan University
Not applicable
48
Shanghai
2023-02-25
Recruiting
GeneCradle Inc
Phase 1/2
18
Beijing, Shenyang, Suzhou
2023-02-25
Recruiting
Domestic Violence Enhanced Perinatal Care Program in China
NCT05388565Intimate Partner Violence
University of Texas at Austin
Not applicable
100
Jinan
2023-02-25
Recruiting
Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children.
NCT06369714Attention Deficit Disorder With Hyperactivity, Executive Function Disorder
DrugConcerta
Lei Lei, MD
Not applicable
210
Shanghai
2023-02-24
Active, closed
A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours
NCT05717348Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor
DrugES014
Elpiscience (Suzhou) Biopharma, Ltd.
Phase 1
120
Shanghai
2023-02-24
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
146
Guangzhou, Changchun, Chengdu
2023-02-23
Recruiting
Chinese PLA General Hospital
Phase 1/2
40
Beijing
2023-02-23
Recruiting
Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
NCT06254560Severe Aplastic Anemia, Platelet Transfusion Refractoriness
DrugRituximab
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2023-02-23
Recruiting
First Affiliated Hospital of Guangxi Medical University
Early Phase 1
5
Nanning
2023-02-22
Rows per page Showing 15501–16000 of 19187
Previous 30 31 32 33 34 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-china?page=32

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

How many clinical trials are recruiting in China?

11,790 of the 19,187 studies in this register are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 3,998 have not yet opened recruitment, 2,715 are active but closed to new participants, and 684 are enrolling by invitation only. Eligibility for any study is decided by its study team.

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Breast Cancer (423) Advanced Solid Tumors (187) Colorectal Cancer (179) Gastric Cancer (175) Hepatocellular Carcinoma (154) Advanced Solid Tumor (153) Non-Small Cell Lung Cancer (145) Solid Tumor (142) Acute Ischemic Stroke (140) Lung Cancer (135) Non-small Cell Lung Cancer (132) Pancreatic Cancer (131) Multiple Myeloma (128) Coronary Artery Disease (122) Prostate Cancer (110)
→

Browse trials by site location

Beijing (5576) Shanghai (3879) Guangzhou (3345) Hangzhou (1819) Wuhan (1343) Chengdu (1307) Nanjing (1211) Changsha (1154) Chongqing (1078) Fuzhou (1040) Tianjin (934) Zhengzhou (931) Hefei (896) Jinan (783) Changchun (639)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.